Gibbs Mura encourages investors to contact us about their legal rights and options in the Hims & Hers Health, Inc. (NYSE: HIMS) Securities Class Action Lawsuit . What Should Hims & Hers Investors Do?

The drugmaker Novo Nordisk is slated to report its second-quarter financial results early Wednesday, after shares plunged ...

Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

By Christy Santhosh (Reuters) -Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United ...

Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...

Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve ...

For outsourcing and manufacturing professionals, 2024 may be remembered as the year capacity and partnerships took center ...

The telehealth company posted revenue of $544.8 million in the second quarter, marking a 73% increase year over year but missing analyst estimates for $552 million, according to Bloomberg data. Hims & ...